Myriad Genetics, Inc.
MYGN
$7.42
$0.050.68%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 51.65% | 57.73% | 37.47% | -60.47% | -135.09% |
| Total Depreciation and Amortization | 8.90% | 12.23% | -8.74% | -11.17% | 6.64% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 61.56% | -13.45% | 12.61% | 23.82% | 89.59% |
| Change in Net Operating Assets | -301.48% | -178.23% | -161.12% | 160.91% | 132.34% |
| Cash from Operations | 92.16% | -10.24% | -109.95% | -3.55% | -4.33% |
| Capital Expenditure | 69.94% | 62.54% | 56.03% | 25.76% | -39.51% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -101.79% | -101.05% | -96.88% | -69.01% | 280.40% |
| Cash from Investing | -137.30% | -316.87% | -226.13% | -512.50% | 141.16% |
| Total Debt Issued | 50.00% | 250.00% | 200.00% | -- | -- |
| Total Debt Repaid | -198.26% | -140,300.00% | -- | -- | -- |
| Issuance of Common Stock | -95.23% | 5,175.00% | 3,736.36% | 1,960.00% | 1,861.90% |
| Repurchase of Common Stock | -52.27% | -55.68% | -24.04% | -21.15% | 16.98% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 97.83% | 94.12% | 54.05% | 54.05% |
| Cash from Financing | -104.84% | 288.93% | 306.47% | 1,939.51% | 2,011.25% |
| Foreign Exchange rate Adjustments | -266.67% | -33.33% | -300.00% | -300.00% | 200.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -138.93% | 196.50% | -276.92% | 141.46% | 138.72% |